ArticleEndocrine journal2026
Establishment of a prognostic score for distant recurrence in follicular thyroid carcinoma.
Article in Endocrine journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Follicular thyroid carcinoma (FTC) is known to occasionally show distant recurrence (DR); however, no prognostic scoring system has been established. Furthermore, although prognostic factors have been identified, their weights as predictors of poor prognosis remain unclear. In this study, we aimed to establish a weighted scoring system for predicting DR in FTC using conventional prognostic factors and Ki-67 labeling index (LI). We analyzed data of 597 patients with FTC without distant metastasis at initial surgery. Tumor size >4 cm, male sex, age ≥60 years, Ki-67 LI >5%, and vascular invasion (VI) ≥4 (V2) significantly and VI 0-4 (V1) marginally affected DR. Wide capsular invasion was not significantly associated with DR. Stepwise model selection using the Akaike Information Criterion identified age ≥60 years, Ki-67 LI >5%, V1, V2, and tumor size >4 cm as suitable components of the score. According to the beta coefficient value, we assigned a score of 2 to age ≥60 years, Ki-67 LI >5%, and V2, and a score of 1 to tumor size >4 cm and V1, with the sum representing the final score. We categorized patients into three categories according to the DR rates: low-risk (score 0-2; n = 388, 65.0%), intermediate-risk (score 3-4; n = 156, 26.1%), and high-risk (score 5-7; n = 53, 8.9%). The 10-year DR-free survival rates declined from the low- to the high-risk categories (96.0% vs. 90.3% vs. 54.9%). These findings indicate that high-risk patients identified using this prognostic scoring model should be carefully monitored for DR following completion thyroidectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.